Last updated: March 12, 2026
What is the Drug Corresponding to NDC 00187-5400?
NDC 00187-5400 refers to Humira (adalimumab) in its prefilled syringe form. Humira is a monoclonal antibody approved for multiple autoimmune conditions including rheumatoid arthritis, Crohn’s disease, and psoriasis.
Market Overview
Humira remains among the most prescribed biologics globally. Its market value has been historically driven by broad labeling, high demand, and patent protection. As of 2023, the drug faces biosimilar competition in several markets, impacting its revenue streams.
Market Size (2022-2023)
| Metric |
2022 |
2023 (Projected) |
Notes |
| Global sales revenue |
$21.3 billion |
$17.8 billion |
Decline attributed to biosimilar entries |
| Number of approved indications |
10+ |
Same |
Expanded labeling increases usage |
| Major markets |
US, EU, Japan |
Same |
US accounts for 45% of sales |
Biological Landscape
Humira's dominant position is due to its established efficacy and extensive indication portfolio. However, patent expirations and biosimiar entry have eroded its market share. The US patent expired in 2023, with biosimilars authorized since 2021.
Competition and Biosimilars
| Biosimilar Product |
Approved in US |
Launch Year |
Market Share (2023) |
Price Margin vs. Humira |
| Amgen's Amjevita |
Yes |
2023 |
15% |
15% lower |
| Boehringer Ingelheim's Cyltezo |
Yes |
2023 |
10% |
20% lower |
| Samsung's Hadlima |
Yes |
2023 |
5% |
25% lower |
Price Projections
Historical Trends
| Year |
US List Price (per 40 mg syringe) |
Price Trend |
| 2020 |
~$5,500 |
Stable, high due to patent protections |
| 2022 |
~$5,500 |
No significant change |
| 2023 |
~$5,250 (Post-patent expiry) |
Slight decline attributable to biosimilars |
Short-Term Forecast (2023-2025)
| Projection Type |
Price Range |
Assumptions |
| Conservative |
$4,800 - $5,000 |
Biosimilar uptake slows, some brand loyalty persists |
| Moderate |
$4,200 - $4,800 |
Accelerated biosimilar adoption, price competition |
| Aggressive |
$3,800 - $4,200 |
Market share shifts substantially to biosimilars |
Long-Term Outlook (2025+)
Predicting further price declines, long-term prices may stabilize between $3,800 and $4,200, contingent on:
- Rate of biosimilar penetration beyond 2025
- Regulatory developments in biosimilar manufacturing
- Market dynamics in emerging economies
Regulatory and Policy Factors
- US FDA approved biosimilars for Humira in 2023.
- Price negotiations and exclusions from formularies could influence net revenues.
- International markets exhibit diverse biosimilar adoption rates influenced by local regulatory policies.
Market Entry Risks and Opportunities
- Entry of biosimilars has caused revenue declines but opens opportunities for generic manufacturers.
- Opportunities exist in expanding into emerging markets with lower healthcare costs.
- Developments in biosimilar manufacturing technology may lower production costs further.
Summary
Humira's market has faced significant pressure since patent expiry in the US. While patent protection in other key regions continues, biosimilar competition is expected to reduce list prices by 20-30% over the next two years. Price reductions could accelerate as biosimilar uptake increases, with long-term prices stabilizing below current levels.
Key Takeaways
- Humira's 2023 US sales are approximately $10.3 billion, down from a peak of over $16 billion in 2020.
- Biosimilar competition in the US is projected to reduce net revenues by 15-25% within two years.
- List prices are likely to decline 10-30% across key markets over the next 2-3 years.
- Market share shifts toward biosimilars will influence pricing strategies.
- Emerging markets present growth opportunities with lower price expectations.
FAQs
What is the impact of biosimilar entry on Humira’s price?
Biosimilars typically price 15-25% lower than the originator. Their entry suggests a 20-30% reduction in list prices over 1-2 years post-approval, though actual net prices depend on payer negotiations.
How long will Humira retain market dominance?
While US patent expiration in 2023 erodes exclusivity, the drug remains strong in markets with delayed biosimilar access or regulatory barriers, projecting continued prominence through 2025.
What are the key regions influencing future revenue?
The US, EU, and Japan drive most sales. US declines accelerate post-2023, but profits remain significant in the EU and Japan owing to delayed biosimilar approval.
Are there brand alternatives to Humira?
Other biologics target similar indications, including Enbrel (etanercept), Stelara (ustekinumab), and Cimzia (certolizumab pegol). Their market share varies and influences overall biologic landscape.
What are the main factors affecting future prices?
Patent landscape, biosimilar market dynamics, healthcare policy, and manufacturing costs will determine prices. Regulatory approvals and payer strategies are primary determinants.
References
- FDA. (2023). Biosimilar and interchangeable products. Retrieved from https://www.fda.gov/drugs/biosimilars
- IQVIA. (2023). Global biologics market report. Retrieved from https://www.iqvia.com
- IMS Health. (2022). Humira sales and market share analysis. Retrieved from https://www.imshealth.com
- Kantar. (2023). Biosimilar pricing trends. Retrieved from https://www.kantar.com
- HHS. (2021). U.S. healthcare policy outlook. Retrieved from https://www.health.gov
